BR0208007A - Preparação para a determinação da capacidade metabólica da pirimidina - Google Patents

Preparação para a determinação da capacidade metabólica da pirimidina

Info

Publication number
BR0208007A
BR0208007A BR0208007-9A BR0208007A BR0208007A BR 0208007 A BR0208007 A BR 0208007A BR 0208007 A BR0208007 A BR 0208007A BR 0208007 A BR0208007 A BR 0208007A
Authority
BR
Brazil
Prior art keywords
pyrimidine
preparation
determination
capacity
fluoruracil
Prior art date
Application number
BR0208007-9A
Other languages
English (en)
Inventor
Makoto Inada
Nobuhiro Ikei
Hideji Nonomura
Yasuo Irie
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR0208007A publication Critical patent/BR0208007A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1815—Suspensions, emulsions, colloids, dispersions compo-inhalant, e.g. breath tests
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"PREPARAçãO PARA A DETERMINAçãO DA CAPACIDADE METABóLICA DA PIRIMIDINA". A presente invenção refere-se a um método para a medição e para a avaliação da capacidade em um sujeito individual para a metabolização de uma variedade de drogas de fluoruracila, tais como a 5-fluoruracila, as quais são degradadas no trajeto de metabolização da pirimidina, e uma preparação que pode ser utilizada para a medição e para a avaliação. A presente invenção pode ser executada através de: administrar uma preparação para a determinação da capacidade de metabolização da pirimidina que compreende como um ingrediente ativo um composto de pirimidina ou um composto metabólico da pirimidina que atua como um substrato para uma enzima de metabolização da pirimidina, em que pelo menos um dos átomos de carbono, oxigênio e nitrogênio é rotulado com um isótopo; e avaliando in vivo a capacidade de metabolização da pirimidina com base no comportamento de um metabólito excretado.
BR0208007-9A 2001-03-13 2002-03-13 Preparação para a determinação da capacidade metabólica da pirimidina BR0208007A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001070828 2001-03-13
PCT/JP2002/002351 WO2002072153A1 (fr) 2001-03-13 2002-03-13 Agents permettant de mesurer la capacite de la pyrimidine a etre metabolisee

Publications (1)

Publication Number Publication Date
BR0208007A true BR0208007A (pt) 2004-03-02

Family

ID=18928628

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208007-9A BR0208007A (pt) 2001-03-13 2002-03-13 Preparação para a determinação da capacidade metabólica da pirimidina

Country Status (12)

Country Link
US (2) US6797256B2 (pt)
EP (1) EP1374911B1 (pt)
JP (1) JPWO2002072153A1 (pt)
KR (1) KR20030082973A (pt)
CN (2) CN100341580C (pt)
BR (1) BR0208007A (pt)
CA (1) CA2440372C (pt)
ES (1) ES2438728T3 (pt)
HK (1) HK1065954A1 (pt)
MX (1) MXPA03008343A (pt)
TW (1) TWI239248B (pt)
WO (1) WO2002072153A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060199269A1 (en) * 2005-03-07 2006-09-07 Schneider David R Method for assessing pyrimidine metabolism
CN101232905B (zh) * 2005-07-25 2013-01-09 大塚制药株式会社 一种用于测量嘧啶代谢能力的口服制剂
JP5213702B2 (ja) * 2006-04-13 2013-06-19 大塚製薬株式会社 ディスペプシア診断検査薬
KR102105354B1 (ko) 2012-08-20 2020-04-29 오츠카 세이야쿠 가부시키가이샤 당대사능의 측정 방법 및 그에 사용하는 조성물
ES2754246T3 (es) 2013-03-15 2020-04-16 Otsuka Pharma Co Ltd Composición para su uso en un método para medir la razón de combustión azúcar/ácido graso

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328229A (en) * 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5077034A (en) * 1990-03-30 1991-12-31 The President And Fellows Of Harvard College Treatment of tumors with 5-radioiodo-2'-deoxyuridine
US5248771A (en) * 1991-06-26 1993-09-28 Triumf Process for preparing no-carrier-added radiohalogenated vinyl nucleosides
US5670331A (en) * 1995-06-22 1997-09-23 The University Of Alabama Research Foundation Methods for optimizing fluoropyrimidine cancer therapy
US5707602A (en) 1996-03-25 1998-01-13 Meretek Diagnostics Measurement of gastric emptying
US5944670A (en) * 1996-12-02 1999-08-31 Oridion Medical Ltd. Breath test for the diagnosis of bacterial infection
AU745236B2 (en) * 1997-02-14 2002-03-14 George Washington University, The An assay for the measurement of DNA synthesis rates
IT1302026B1 (it) 1997-08-22 2000-07-20 Hoffmann La Roche Materiali immunologici e metodi per la rivelazione di diidropirimidinadeidrogenasi.

Also Published As

Publication number Publication date
JPWO2002072153A1 (ja) 2004-07-02
EP1374911A1 (en) 2004-01-02
TWI239248B (en) 2005-09-11
US20020132283A1 (en) 2002-09-19
KR20030082973A (ko) 2003-10-23
HK1065954A1 (en) 2005-03-11
EP1374911B1 (en) 2013-10-16
CN101138638A (zh) 2008-03-12
US20040234452A1 (en) 2004-11-25
EP1374911A4 (en) 2007-06-20
ES2438728T3 (es) 2014-01-20
WO2002072153A1 (fr) 2002-09-19
CN1498116A (zh) 2004-05-19
MXPA03008343A (es) 2003-12-11
US6797256B2 (en) 2004-09-28
CN100341580C (zh) 2007-10-10
CA2440372C (en) 2009-09-15
CA2440372A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
Hostrup et al. Limitations in intense exercise performance of athletes–effect of speed endurance training on ion handling and fatigue development
Jubrias et al. Acidosis inhibits oxidative phosphorylation in contracting human skeletal muscle in vivo
Dreyer et al. Resistance exercise increases AMPK activity and reduces 4E‐BP1 phosphorylation and protein synthesis in human skeletal muscle
Bogdanis et al. Power output and muscle metabolism during and following recovery from 10 and 20 s of maximal sprint exercise in humans
Lorenz et al. Metabolome response to glucose in the β-cell line INS-1 832/13
Lentz et al. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA
Mogensen et al. Cycling efficiency in humans is related to low UCP3 content and to type I fibres but not to mitochondrial efficiency
Eskurza et al. Tetrahydrobiopterin augments endothelium‐dependent dilatation in sedentary but not in habitually exercising older adults
Hindorf et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease
Jaworowski et al. Enzyme activities in the tibialis anterior muscle of young moderately active men and women: relationship with body composition, muscle cross‐sectional area and fibre type composition
Ladurner et al. Ascorbate stimulates endothelial nitric oxide synthase enzyme activity by rapid modulation of its phosphorylation status
McConell et al. Skeletal muscle AMPK is not activated during 2 h of moderate intensity exercise at∼ 65% in endurance trained men
Beysen et al. Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: results from two early‐phase randomized trials
Marcuzzi et al. Natural isoprenoids inhibit LPS-induced-production of cytokines and nitric oxide in aminobisphosphonate-treated monocytes
Merry et al. N‐Acetylcysteine infusion does not affect glucose disposal during prolonged moderate‐intensity exercise in humans
McGinley et al. Distinct protein and mRNA kinetics of skeletal muscle proton transporters following exercise can influence interpretation of adaptations to training
Badner et al. Preoperative oral B vitamins prevent nitrous oxide-induced postoperative plasma homocysteine increases
Jensen et al. Variability and heritability of thiamine pharmacokinetics with focus on OCT1 effects on membrane transport and pharmacokinetics in humans
WO2004088279A3 (en) Allosteric probes and methods
Metzler et al. Clindamycin dose-bioavailability relationships
Grosicki et al. Single muscle fibre contractile characteristics with lifelong endurance exercise
Kuklin et al. Tezosentan-induced attenuation of lung injury in endotoxemic sheep is associated with reduced activation of protein kinase C
BR0208007A (pt) Preparação para a determinação da capacidade metabólica da pirimidina
Stephens et al. 5′‐Aminoimidazole‐4‐carboxyamide‐ribonucleoside‐activated glucose transport is not prevented by nitric oxide synthase inhibition in rat isolated skeletal muscle
Sherwood et al. The effect of eccentric exercise on serum creatine kinase activity in different ethnic groups

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2055 DE 25/05/2010.